NCT03747497View on ClinicalTrials.gov

Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

November 15, 2018

Primary Completion Date

March 26, 2019

Study Completion Date

March 26, 2019

Conditions
Skin Diseases, BacterialGram-Positive Bacterial Infections
Interventions
DRUG

contezolid acefosamil

IV and oral contezolid acefosamil given twice a day for 10 to 14 days

DRUG

linezolid 600 mg

IV and oral linezolid given twice a day for 10 to 14 days

Trial Locations (7)

59701

MicuRx Site #107, Butte

89106

MicuRx Site #105, Las Vegas

89109

MicuRx Site #108, Las Vegas

90806

MicuRx Site #102, Long Beach

91911

MicuRx Site #106, Chula Vista

91942

MicuRx Site #103, La Mesa

95204

MicuRx Site #104, Stockton

Sponsors

Lead Sponsor

MicuRx
All Listed Sponsors
lead

MicuRx

INDUSTRY

NCT03747497 - Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection | Biotech Hunter | Biotech Hunter